New antibody combo aims to boost lymphoma remission

NCT ID NCT06829771

Recruiting now Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called TQB2825, a bispecific antibody that helps immune cells attack lymphoma cells, combined with standard R-CHOP chemotherapy. The trial enrolls 90 adults with untreated or relapsed/refractory diffuse large B-cell lymphoma. Researchers will measure how well the tumors shrink and how long the effects last, while also checking for side effects to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB2825 (a bispecific antibody targeting CD20 and CD3) plus R-CHOP chemotherapy
What this could lead to: If successful, this combination could improve response rates and extend remission in people with diffuse large B-cell lymphoma, especially those who have relapsed or not responded to prior therapy.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 90 participants, so safety and efficacy are not yet established. The added bispecific antibody may increase side effects like cytokine release syndrome or immune-related toxicities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Affiliated Cancer Hospital of Shandong First Medical University
NOT_YET_RECRUITING

Jinan, Shandong, 250117, China
Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Fudan university shanghai cancer center
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Fujian Cancer Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, 350014, China
Gansu Provincial Cancer Hospital
NOT_YET_RECRUITING

Lanzhou, Gansu, 730000, China
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 457000, China
Hubei Cancer Hospital
NOT_YET_RECRUITING

Wuhan, Hubei, 430079, China
Jiangsu Provincial People's Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210000, China
Jiangxi Canser Hospital
NOT_YET_RECRUITING

Nanchang, Jiangxi, 330029, China
Liuzhou People's Hospital
NOT_YET_RECRUITING

Liuzhou, Guangxi, 545006, China
Maanshan People's Hospital
RECRUITING

Ma’anshan, Anhui, 243000, China
People's Hospital of Tianjin (City)
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300000, China
Puyang Oilfield General Hospital
NOT_YET_RECRUITING

Puyang, Henan, 457001, China
Shanxi Cancer hospital
NOT_YET_RECRUITING

Taiyuan, Shanxi, 30000, China
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510000, China
The Affiliated Hospital of Southwest Medical University
NOT_YET_RECRUITING

Luzhou, Sichuan, 646000, China
The Affiliated Hospital of Xuzhou Medical University
NOT_YET_RECRUITING

Xuzhou, Jiangsu, 221000, China
The First Affiliated Hospital of Bengbu Medical College
NOT_YET_RECRUITING

Bengbu, Anhui, 233000, China
The First Affiliated Hospital of Xi'an Jiao Tong University
NOT_YET_RECRUITING

Xi'an, Shannxi, 710000, China
The First Hospital of Jilin University
NOT_YET_RECRUITING

Changchun, Jilin, 130021, China
The Second Affiliated Hospital of Fujian Medical University
RECRUITING

Quanzhou, Fujian, 362000, China
The second Hospital of dalian
NOT_YET_RECRUITING

Dalian, Liaoning, 116000, China
Tianjin Medical University Cancer Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300060, China
Yantai Yuhuangding Hospital
NOT_YET_RECRUITING

Yantai, Shandong, 26400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.